KB
Kenneth Bate (Director) filed 3 Form 4 reports in the past 24 months (0 purchases, 3 sales), most often in Madrigal Pharmaceuticals, Inc. (MDGL). The largest single filing was $8.0M of MDGL (16,545 sh across 10 lots, as filed), executed Nov 5 2025. Data as of Nov 7 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$18.6M
shares × price, as filed
Last traded
Nov 5 2025
Filed Nov 7 2025
Median ADV $194.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $18.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 24 months
Most traded names
MDGLRecent filings
MDGLSALE
Madrigal Pharmaceuticals, Inc.
View filing →
$8.0M16,545 sh across 10 lots
Exec Nov 5 2025
Filed Nov 7 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $3.7M
10,000 sh across 6 lots
Exec Aug 15 2025
Filed Aug 15 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $6.9M
19,446 sh across 6 lots
Exec Feb 27 2025
Filed Feb 28 2025 · 5:30 PM ET